Kouki Harasaki, Ph.D., Andreessen Horowitz

Kouki Harasaki, Ph.D. Kouki Harasaki is a Partner at the Menlo Park-based venture capital firm Andreessen Horowitz. He began his career in clinical research and lab research positions at the Cleveland Clinic Foundation and the National Institutes of Health, respectively. Since winning a UK national biotech competition in 2003, he has been focused on developing new technologies that impact patients.   After earning his PhD, he spent six years in drug discovery, animal pharmacology, strategy, finance, and business development positions at Novartis AG. There, he negotiated a partnership with Atreca, a biotechnology company focused on developing novel cancer immunotherapies. He then became Senior Director of Business Development at Baxalta (now Shire/Takeda). There, he was instrumental in building the oncology pipeline by negotiating $5 billion in licensing transactions, including the co-development of the marketed pancreatic cancer drug ONIVYDE® (Merrimack Pharmaceuticals), novel checkpoint inhibitors (Symphogen), allogeneic CAR-T cell therapies (Precision BioSciences ARCUS genome editing platform), and biosimilars (Momenta Pharmaceuticals).   After the $32 billion acquisition of Baxalta by Shire in 2016, Kouki became a Blavatnik Fellow (healthcare entrepreneur-in-residence) at Harvard and ran Medal (San Francisco-based medical data machine learning and analytics company) as COO. Under his tenure, Medal raised venture financing (investors include 8VC, Founders Fund, Draper Associates, Zhen Fund, SAP.iO, Alpha Edison), grew from 3 to 14+ FTE, achieved HITRUST data security certification, and became revenue-positive. Kouki also led negotiations with payers, providers, and multinational technology corporations.   Kouki earned a BA in Molecular/Cell Biology and Asian Studies from Cornell University, a PhD in Clinical Biochemistry from the University of Cambridge (Wellcome Trust Fellow), and an MBA from Harvard Business School (Robert S. Kaplan Life Sciences Fellow). He is currently a board member of the Harvard Business School Healthcare Alumni Association.

Download Latest Agenda